Form 4: ARTL CEO Gorgas Granted 154,713 Stock Options

ARTELO BIOSCIENCES, INC. CEO Gregory D. Gorgas was granted 154,713 stock options with an exercise price of $1.68, vesting over four years.

Summary

• Gregory D. Gorgas, who serves as Director, President, CEO, CFO, Treasurer, and Secretary of ARTELO BIOSCIENCES, INC. (ARTL), was granted 154,713 stock options.
• The stock options have an exercise price of $1.68 per share.
• The transaction date for the option grant was January 29, 2026, and the options are exercisable from this date, expiring on January 29, 2036.
• Vesting for the options commences on January 1, 2026, with one forty-eighth (1/48th) of the shares vesting each month following this date.
• The options will be fully vested on the four-year anniversary of the Vesting Commencement Date, contingent on Mr. Gorgas continuing to be a Service Provider as defined in the Issuer's 2018 Equity Incentive Plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signals management's continued commitment and aligns executive incentives with long-term shareholder interests through a standard equity grant.

Positives

• The grant of stock options aligns management's interests with shareholder value creation, as the options become more valuable if the stock price increases above the exercise price.
• The four-year vesting schedule encourages long-term commitment and retention of a key executive, fostering stability in leadership.

Negatives

• The value of the options is contingent on the company's stock price exceeding the $1.68 exercise price, meaning they hold no intrinsic value if the stock trades below this threshold.

Risks

• The options are subject to a four-year vesting schedule, and if Gregory D. Gorgas ceases to be a Service Provider before full vesting, unvested options may be forfeited.
• The ultimate financial benefit from these options is dependent on the future market price of ARTELO BIOSCIENCES, INC. common stock appreciating above the $1.68 exercise price.

Future Outlook

The filing indicates a long-term incentive structure for a key executive, suggesting an expectation of continued service and future value creation over the four-year vesting period, aligning executive performance with shareholder interests.

Industry Context

StockSavvy.ai notes that granting stock options to key executives like the CEO is a standard practice across industries to align management incentives with long-term shareholder value. This particular grant size and vesting schedule are typical for a company of ARTELO BIOSCIENCES' profile, aiming to retain talent and motivate performance.

Comparison to Industry Standards

• The four-year monthly vesting schedule is a common industry standard for executive equity grants, similar to practices seen at biotech peers like Xencor (XNCR) or smaller pharmaceutical companies, which use such structures to ensure long-term executive retention and performance alignment.
• An exercise price set at the market price on the grant date (implied by the $0.00 price of derivative security and $1.68 exercise price) is standard for incentive stock options, ensuring the executive benefits only if the stock appreciates.

Stakeholder Impact

• Shareholders: Potential positive impact through increased alignment of executive incentives with long-term stock performance.
• Employees: No direct impact mentioned, but a stable executive team can benefit overall company morale and direction.

Next Steps

• Continued service of Gregory D. Gorgas as a Service Provider for the options to vest.
• Monthly vesting of 1/48th of the options commencing January 1, 2026, over four years.
• Potential exercise of vested options by Gregory D. Gorgas before the expiration date of January 29, 2036.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to a key executive as part of their compensation package. While it signals continued executive commitment and aligns interests with shareholders, it does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. It's a standard compensation event.

Keywords

ARTELO BIOSCIENCES, ARTL, Stock Options, Executive Compensation, Form 4, Insider Transaction, Gregory D. Gorgas, Equity Incentive Plan, Vesting